Celera Group
http://www.celera.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celera Group
Finance Watch: Investors Launch New SPACs After Initial Deals
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
Russia’s RDIF and Sberbank Launch $100m Start-Up Fund
Russian sovereign wealth fund and Sputnik V vaccine producer RDIF has teamed up with the country’s biggest bank to fund ‘home-grown’ tech and science-intensive start-ups.
Coronavirus Update: CoVIg-19 Alliance Ends As Trial Misses Endpoints
Global research consortium to investigate the use of immunoglobulin as a COVID-19 therapy ends following disappointing results from a Phase III trial. Meanwhile, Russian vaccine producer RDIF is snapping up more production capacity in India, where interferon has also progressed as a possible treatment.
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio